BriaCell Therapeutics Corp.
BCTXHealthcareNASDAQBiotechnology · Last scanned Sep 4, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of Sep 3
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. The $30.7M market capitalization puts BCTX squarely in micro-cap range for its industry. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Market Cap
$30.7M
Beta
1.52
P/E (TTM)
—
P/E (Fwd)
-9.05
EPS (TTM)
$-0.83
EPS (Fwd)
$-0.39
ROE
-175.3%
ROA
-90.8%
Cash
$22.8M
Total Debt
$0
Free CF
-$20.0M
52W Change
-53.8%
Annual Financials
Cash vs Debt
Where BCTX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BCTX finished 5.56% below its 150-day moving average ($3.78) and 26.54% below its 200-day moving average ($4.86). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BCTX overbought or oversold?
At the September 3, 2026 close, BCTX's RSI(14) was 52.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
BriaCell Therapeutics Corp. reports $22.8M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$20.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -175.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, BCTX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BriaCell Therapeutics Corp. and its sector.